Risky
XRP_USD(RIPPPLE) WHATS GOING ON? TRADE IDEA SUGGESTION|
In the Video I examine the reasons why XRP fell so dramatically
While the other crypto currencies are surging
I then proceed to suggest a small risky fundamental trade
That might have x5 to x20 risk return
If you want to learn more, I invite you to watch the whole video.
Thank for watching, like and subscribe to never miss a new idea!
#QLC - risk takers risking a long/buy here, risky coz BTC is being BTC also wedge not yet broken
#notfinancialadvisor
#DoYourOwnResearch
LTCUSD Risky LongHi
As you can see in my chart, there is a possible channel which has a lot of breakout or takeout during the time, and the price has broken it with strong momentum, that why I'll go with a long position till 48 prices. That might be a barrier. I put the stop below the price shadows on the channel. Take this trade at your own risk.
Why? Because in a bigger picture, the price has broken a more significant channel form downside, but I think it will bounce back in it. (I haven't drawn the channel in the chart.)
------------------------------------------------
What is your opinion? Comment it below.
If you like the idea, please hit the like button and subscribe to the profile to not miss my updates. The information given is never financial advice. Always do your research too.
Goodluck.
NZD/USD SELL SIGNAL Hey tradomaniacs,
welcome to another free trade-plan .
Important:
This is a high risk trade that I personally execute as NZD/USD looks like a very nice short after the previous rejection.
Keep in mind that fundamentals are currently driving the market so If the stock-market continues to climb NU will do that aswell.
I keep my risk very low on this trade as it gives me a very nice risk-reward in this case.
Note this before you decide to follow this trade or not. if you have a low risk-appetite please stay out.
Market-Sell-Order: 0,64550
Stop-Loss: 0,65310
Target 1: 0,63550
Target 2: 0,62890
Target 3: 0,62000
Stop-Loss: 76 pips
Risk: 1%
RIsk-Reward: 3,40
LEAVE A LIKE AND A COMMENT - I appreciate every support! =)
Peace and good trades
Irasor
Wanna see more? Don`t forget to follow me.
Any questions? PM me. :-)
Risky idea but nice profit BUY IRBT @ 49 -52Caution! High volatility stock (5-7% volatility daily).
Buy IRBT at the levels of $49-$52 (Avg price of $50,5).
Take @ $60 ((+18,8%)
Stop @ $46,6 (-7,7%)
The price is at it's 52w lows. Very cheap to buy
If the price slumps below 47, it is better to fix a loss due to high volatility of the stock.
TAEL(WABI) Wants to Show It's not Dead.... YetI loved trading wabi so for
Last two days showed it wants to play more
It may show a little pullback into our support, i will add more if it comes to that
This was a monster coin last season, lets see what it can offer us in the future
Akorn Inc. LongThe price of akorn inc. recently dived due to the news of possible bankrupcy, in addition to a Head and Shoulders pattern. Price has most likely reached its low and will likely impulse in a new continuation, confirming the Bull Flag. Price has also hit the bottom of a high time frame expanding structure and will likely go a lot higher. Many sites and analysts indicate that the stock is underpriced, good short/medium term hold, but is something of a risky trade. First target will be around 25%.
L/S Swedish Equities Pairs TradeConsumer Defensive / Consumer Cyclical
30/12/2019 Close
Long: ESSITY_B Current Price SEK: 301.80
Short: WESC_AB Current Price SEK: 0.0046
ESSITY / WESC spread Entry Range: 65608.70
ESSITY / WESC spread Hard Stop: 59076.70 (10%)
ESSITY / WESC spread Soft Target: 85374.00 (30%)
BETA hedge
For every SEK 1.00 Long of ESSITY_B
SEK 9.00 Short of WESC_AB
*Build you position in two stages enter with 50% of desired exposure.
*+add too the position on a breakout or at the soft target.
*Hedge your currency exposure, unless you have a view on SEK.
*HIGH RISK trade.
Essity: Consumer Defensive (Manufacture Tissues, Toilet paper & other hygiene products) Strong fundamentals, very defensive and predictable earnings with consistent global demand, outperformed all of its competitors in 2019.
*Market Cap = 212B
*EPS = 14.10
ESSITY_B Consensus Jan 2020 =F1 Jan 2021 =F2
F1 P/E: 20.10x
F2 P/E: 17.60x
F1 Earnings Growth: 22.38%
F2 Earnings Growth: 6.70%
F1 Sales Growth: 2.70%
F2 Sales Growth: 3.00%
F1 PEG: 0.89
F2 PEG: 2.62
Risk: Reflation of the global economy, and solid resolution of political tensions. And therefore a full risk on scenario and defensive stock underperformance.
Wesc: Consumer Cyclical (Trades Apparel & related products, under it brand name WESC) Weak fundamentals, very cyclical and “polluting” as it’s fast low quality fashion. Loss making. In desperate need of a turn around, I feel the business will not attract new talent (As the brand is notoriously NOT cool for millennials and gen z) and isn’t worth turning around as a brand, also no analyst and very hard to find relevant financial information in for the company.
*Market cap = 22M
*EPS = -0.0150
Risk: Merger, acquisition or turnaround. Otherwis I’d be happy to keep this position on for the foreseeable future.
*KEEP YOUR POSITION SIZE SMALL*
This is a risky pairs trade as WESC could get bought out, or turned around and go to infinity, but I’m betting against that.
LONG High quality Swedish Consumer Staple.
SHORT Low quality Swedish Consumer Cyclical.
LXRX - Bullish But Risky Move. Pullback ComingLexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
SHORT INTEREST
7.74M 08/15/19
P/E Current
-1.51
P/E Ratio (with extraordinary items)
-2.05
Average Recommendation: OVERWEIGHT
Average Target Price: 8.00
VVUS - Risky But Moving Up And Reclaiming LossesVIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.
SHORT INTEREST
541.95K 07/31/19
P/E Current
-1.14
P/E Ratio (with extraordinary items)
-1.53
Average Recommendation: HOLD
Average Target Price: 10.00
RISKY CLRO - 87% UP YTD. CAN THIS TREND REMAIN BULLISH?ClearOne, Inc. engages in the design, development, and sale of conferencing, collaboration, and network streaming solutions for voice and visual communications. Its products include professional audio conferencing, speakerphones, professional microphones, and video collaboration. The company was founded in 1983 and is headquartered in Salt Lake City, UT.
SHORT INTEREST
170.67K 07/31/19
P/E Current
-1.21
P/E Ratio (with extraordinary items)
-2.19
RISKY GOGO TRADE - GOOD END OF YEAR PREDICTED Gogo, Inc. engages in the provision of in-flight broadband connectivity and wireless entertainment services. It operates through the following segments: Commercial Aviation North American (CA-NA); Commercial Aviation Rest of World (CA-ROW); and Business Aviation (BA). The CA-NA segment offers a broad range of connectivity and entertainment services to commercial airlines flying routes. The CA-ROW segment covers satellite-based connectivity and entertainment services to foreign-based commercial airlines and North American based commercial airlines when flying routes outside of North America. The BA segment comprises of a broad suite of in-flight Internet connectivity and other voice and data communications products and services under its Gogo Business Aviation brand to the business aviation market. The company was founded in 1991 and is headquartered in Chicago, IL.
SHORT INTEREST
34.83M 07/15/19
P/E Current
-1.91
P/E Ratio (with extraordinary items)
-2.05
Average Recommendation: OVERWEIGHT
Average Target Price: 6.40
Wait for a pullback on this move...
BMRA - RISKY BUT TREND IS STRONG PULLBACK COMINGBiomerica, Inc. is a biomedical company, which develops, manufactures and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The Company's medical diagnostic products are sold around the world in over two markets, including clinical laboratories and point of care (physicians' offices and over-the-counter drugstores). The Company operates in Europe, the United States, Asia, South America, the Middle East and other foreign countries. The Company's diagnostic test kits are used to analyze blood, urine or fecal specimens from patients in the diagnosis of various diseases and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which exist in the human body in various concentrations. The Company primarily focuses on products for gastrointestinal (GI), food intolerances, diabetes and esoteric tests. The Company's diagnostic products use immunoassay technology.
SHORT INTEREST
22.39K 07/15/19
P/E Current
-19.53
P/E Ratio (with extraordinary items)
-13.60
Average Recommendation: BUY
Average Target Price: 6.25